Research map: Economic evaluation of PET-CT in staging and response assessment of patients with diffuse large B-cell lymphoma (DLBCL) in Thailand: a cost-utility analysis

Back to the article

Papers in this map

  1. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) · Michael Herdman · 2011 · 10327 citations · Cited by this paper
  2. Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system · 2026 · Related
  3. Decision Modelling For Health Economic Evaluation · Andrew H. Briggs · 2006 · 3155 citations · Cited by this paper
  4. How accurate should a precision medical test be to meet cost-effectiveness · 2026 · Related
  5. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study · Michael Crump · 2017 · 1733 citations · Cited by this paper
  6. Financial strain beyond coverage: assessing out-of-pocket costs for dialysis care in chronic kidney disease at a tertiary care centre in Central India · 2026 · Related
  7. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte · Bertrand Coiffier · 2010 · 1591 citations · Cited by this paper
  8. Influence of clinical benefit and cost-effectiveness on reimbursement decisions for lung cancer drugs in Spain · 2026 · Related
  9. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations · Don Husereau · 2022 · 1125 citations · Cited by this paper
  10. Ghana’s Diagnosis Related Grouping (G-DRG) tariffs versus hospital charges: implications for inpatient care financing at a secondary hospital in Ghana · 2026 · Related
  11. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up · Hervé Tilly · 2015 · 936 citations · Cited by this paper
  12. The impact of hospital bed supply on medical insurance expenditure in China (2011–2024): evidence on Roemer’s Law and threshold effects · 2026 · Related
  13. The EQ-5D-5L Valuation study in Thailand · Juntana Pattanaphesaj · 2018 · 209 citations · Cited by this paper
  14. Economic burden of knee replacement, a case of Bushehr, Iran in 2023–2024 · 2026 · Related
  15. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma · T. Lamy · 2017 · 179 citations · Cited by this paper
  16. Costs of venovenous extracorporeal membrane oxygenation (VV-ECMO) and its potential contribution to quality-adjusted life years: a mixed-methods study protocol · 2026 · Related
  17. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? · Pia Raanani · 2005 · 176 citations · Cited by this paper
  18. Extended cost-effectiveness analysis in global health systems: a scoping review of geographic gaps and research trends · 2026 · Related
  19. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry · Nicolas Mounier · 2011 · 118 citations · Cited by this paper
  20. Real-world cost avoidance associated with bevacizumab biosimilar adoption in a tertiary public hospital in Ecuador: a cost-minimization and budget impact analysis · 2026 · Related
  21. Patterns of Failure in Advanced Stage Diffuse Large B-Cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy · Zheng Shi · 2013 · 85 citations · Cited by this paper
  22. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study · Allison Barraclough · 2019 · 52 citations · Cited by this paper
  23. Non‐Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand · Tanin Intragumtornchai · 2017 · 46 citations · Cited by this paper
  24. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi–Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma · Nieves Gómez León · 2017 · 39 citations · Cited by this paper
  25. Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry · Ur Metser · 2018 · 37 citations · Cited by this paper
  26. Health state utilities for skeletal-related events secondary to bone metastases · Louis S. Matza · 2013 · 32 citations · Cited by this paper
  27. Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful · Hina Shah · 2017 · 32 citations · Cited by this paper
  28. Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab? · Narendranath Epperla · 2020 · 32 citations · Cited by this paper
  29. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study · Bente Arboe · 2019 · 26 citations · Cited by this paper
  30. R‐ CHOP therapy alone in limited stage diffuse large B‐cell lymphoma · Naoto Tomita · 2013 · 25 citations · Cited by this paper
  31. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma · Lale Kostakoglu · 2019 · 14 citations · Cited by this paper
  32. Role of radiotherapy in diffuse large B‐cell lymphoma in advanced stages on complete response after administration of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab · Agustín Avilés · 2019 · 9 citations · Cited by this paper
  33. Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study · Yu Ri Kim · 2023 · 3 citations · Cited by this paper
  34. Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group · Kitsada Wudhikarn · 2020 · 2 citations · Cited by this paper
  35. Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma · Karen Yee · 2016 · 1 citation · Cited by this paper
  36. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma · Pattamaporn Boonlerd · 2023 · 1 citation · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)